Atypical ezrin localization as a marker of locally advanced breast cancer

Breast Cancer Research and Treatment

Volumn 134, Issue 3, 2012, Pages 981-988

  Arslan, Alan A ^a,b   Silvera, Deborah ^a   Arju, Rezina ^a   Giashuddin, Shah ^c   Belitskaya Levy, Ilana ^a   Formenti, Silvia C ^a,b   Schneider, Robert J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Breast cancer; ERM proteins; Ezrin; Locally advanced; MTOR

Indexed keywords

EZRIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; INTRACELLULAR SPACE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN TRANSPORT; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84868196221     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2017-5     Document Type: Article

References (34)

1. Bretscher A, Edwards K, Fehon RG (2002) ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586-599
2. Fievet B, Louvard D, Arpin M (2007) ERM proteins in epithelial cell organization and functions. Biochim Biophys Acta 1773:653-660
3. Crepaldi T, Gautreau A, Comoglio PM, Louvard D, Arpin M (1997) Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol 138:423-434
4. Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, Weller M (2001) Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci 21:3360-3368
5. Gautreau A, Poullet P, Louvard D, Arpin M (1999) Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:7300-7305
6. Bonilha VL (2007) Focus on molecules: ezrin. Exp Eye Res 84:613-614
7. McClatchey AI (2003) Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer 3:877-883
8. Brambilla D, Fais S (2009) The Janus-faced role of ezrin in "linking" cells to either normal or metastatic phenotype. Int J Cancer 125:2239-2245
9. Martin TA, Harrison G, Mansel RE, Jiang WG (2003) The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46:165-186
10. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10:182-186
11. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10:175-181
12. Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth MA (1999) High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 258:395-400
13. Chen Z, Fadiel A, Feng Y, Ohtani K, Rutherford T, Naftolin F (2001) Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer 92:3068-3075
14. Song J, Fadiel A, Edusa V, Chen Z, So J, Sakamoto H, Fishman DA, Naftolin F (2005) Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett 220:57-65
15. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Kikuchi A, Yamamoto T, Satoh K, Naftolin F (2002) Ezrin, a membranecytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett 179:79-86
16. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F (1999) Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett 147:31-38
17. Sarrio D, Rodriguez-Pinilla SM, Dotor A, Calero F, Hardisson D, Palacios J (2006) Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 98:71-79
18. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P et al (2007) Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 24:69-78
19. Rustogi A, Budrukkar A, Dinshaw K, Jalali R (2005) Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther 1:21-30
20. Valero VV, Buzdar AU, Hortobagyi GN (1996) Locally advanced breast cancer. Oncologist 1:8-17
21. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) AJCC cancer staging manual. Springer, New York
22. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ (2007) A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 28:501-512
23. Wan X, Mendoza A, Khanna C, Helman LJ (2005) Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65:2406-2411
24. Yu Y, Davicioni E, Triche TJ, Merlino G (2006) The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res 66:1982-1989
25. Geiger KD, Stoldt P, Schlote W, Derouiche A (2000) Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. American J Path 157:1785-1793
26. Weng WH, Ahlen J, Astrom K, Lui WO, Larsson C (2005) Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11:6198-6204
27. Kobel M, Langhammer T, Huttelmaier S, Schmitt WD, Kriese K, Dittmer J, Strauss HG, Thomssen C, Hauptmann S (2006) Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Modern Path 19:581-587
28. Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkila S, Vaheri A, Syrjanen K, Pyrhonen S, Carpen O (2008) Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol 39:1737-1743
29. Agresti A (2002) Categorical data analysis. Wiley, New York
30. Elliott BE, Meens JA, Sen Gupta SK, Louvard D, Arpin M (2005) The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 7(3):R365-R373
31. Li Q, Wu MF, Song AP, Wei JC, Xu G, Lu YP, Ma D (2006) Expression of Ezrin and E-cadherin in invasive ductal breast cancer and their correlations to lymphatic metastasis. Ai Zheng 25:363-366
32. Ma L, Zhang XH, Xing LX, Li YH, Wang XL, Wang YJ (2008) Relationship of ezrin protein expression to the carcinogenesis and prognosis of infitrating breast ductal carcinoma. Zhonghua Zhong Liu Za Zhi 30:279-283
33. Li Q, Wu M, Wang H, Xu G, Zhu T, Zhang Y, Liu P, Song A, Gang C, Han Z et al (2008) Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 261:55-63
34. Sizemore S, Cicek M, Sizemore N, Ng KP, Casey G (2007) Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 67:6183-6191